Threshold Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Threshold Pharmaceuticals, Inc.
Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
Office of Prescription Drug Promotion issued six enforcement letters and launched three research projects in 2021. There were more internal changes as the office switched to electronic submissions of promotional materials and went through year-end reorganization.
ANI Pharmaceuticals and Eton Pharmaceuticals have announced the launch of their Carbaglu rival, with the companies having been granted a Competitive Generic Therapy designation by the FDA, along with 180 days of related exclusivity. ANI has also announced receiving FDA approval for its abbreviated new drug application for Mycobutin rival, Rifabutin capsules for 150mg dose.